ArticleGenes & genomics2025
Targeting phosphofructokinase 2 the isoform PFKFB4 suppresses glioblastoma proliferation and malignancy.
Article in Genes & genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Integrated transcriptomic analysis reveals KRAS-associated gene activation and epigenetic regulation in mutant IDH1 glioma.Genes & genomics · 2026Article
- Targeting phosphofructokinase in cancer: integrating natural products for metabolic reprogramming and therapeutic innovation.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlioblastoma (GBM) is a highly aggressive primary brain tumor associated with poor prognosis and enhanced aerobic glycolysis (the Warburg effect), which facilitates rapid tumor growth and increases malignancy. Phosphofructokinase 2 (PFK2), also referred to as 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB), is a critical regulator of glycolysis and has been linked to tumorigenesis; however, the specific contributions of its isoforms to GBM pathobiology remain insufficiently defined.
objectiveThis study aimed to clarify the isoform-specific function of PFKFB4 in GBM by evaluating its expression pattern, clinical significance, and impact on tumor glycolytic flux, proliferation, and malignancy, as well as to investigate the therapeutic potential of selectively targeting PFKFB4.
methodsWe examined the expression profiles of PFK2 isoforms in GBM using publicly accessible datasets. The clinical relevance was determined by conducting survival analysis using The Cancer Genome Atlas (TCGA) database. Protein expression patterns were identified with the Human Protein Atlas. PFKFB4 expression in GBM cell lines was validated using quantitative real-time PCR and immunoblotting. Functional roles of PFKFB4 were further assessed by employing the selective inhibitor 5-(n-(8-methoxy-4-quinolyl)amino)pentyl nitrate (5MPN). Effects of 5MPN on cell viability, proliferation, glucose uptake, lactate production, migration, invasion, and protein expression (c-Myc, cyclin D1, MMP-2, MMP-9) were evaluated using WST-8 assay, colony formation, 2-NBDG uptake, lactate assay, wound healing, transwell assays, and immunoblotting.
resultsWe found that PFK2 isoforms-notably PFKFB4-are markedly overexpressed in GBM tissues and cell lines, with elevated PFKFB4 expression associated with worse patient prognosis. Pharmacological inhibition of PFKFB4 using the selective small-molecule inhibitor 5MPN reduced the Warburg effect, cell proliferation, and colony formation in GBM cells, while having minimal effects on normal human astrocytes. Additionally, PFKFB4 inhibition diminished GBM cell migration and invasion, coinciding with a reduction in the expression of matrix metalloproteinases MMP-2 and MMP-9.
conclusionThese results underscore the oncogenic role of PFKFB4 in enhancing the Warburg effect and promoting malignant phenotypes in GBM, and support its potential as a therapeutic target for GBM treatment.
Indexed as
Identifiers
41118116What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.